J&J Q3 2026 sales rise 5.9% to $25.4B; raises reported sales guidance

Johnson & Johnson reported third-quarter 2026 worldwide sales of $25.4 billion, up 5.9%, and adjusted EPS of $2.59, down 7.5%. Reported EPS was $0.09 because of a one-time special charge for the proposed talc resolution and the Firefly Bio and Sail deals. The company raised its reported 2026 sales outlook to $101.0-101.4 billion, while adjusted EPS guidance is $11.05-11.15 after about $0.64 of 2026 dilution from the two deals.

• Worldwide sales $25.40B, up 5.9% reported and 6.0% operational
• Adjusted EPS $2.59 (down 7.5% from $2.80); reported EPS $0.09 after special charge
• Innovative Medicine $16.76B (up 7.7%); MedTech $8.64B (up 2.5%)
• Stelara drag of about 690 basis points on Innovative Medicine growth
• 2026 guidance: reported sales $101.0-101.4B; adjusted EPS $11.05-11.15